# A Study of LAM-002A for the Prevention of Progression of COVID-19

> **NCT04446377** · PHASE2 · COMPLETED · sponsor: **OrphAI Therapeutics** · enrollment: 142 (actual)

## Conditions studied

- COVID-19 Disease

## Interventions

- **DRUG:** Apilimod Dimesylate Capsule
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04446377
- **Lead sponsor:** OrphAI Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-15
- **Primary completion:** 2021-03-24
- **Final completion:** 2021-04-19
- **Target enrollment:** 142 (ACTUAL)
- **Last updated:** 2023-08-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446377, "A Study of LAM-002A for the Prevention of Progression of COVID-19". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04446377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*